Skip Navigation

Cardiovascular Research 1997 35(2):184-199; doi:10.1016/S0008-6363(97)00141-7
© 1997 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Antozzi, C.
Right arrow Articles by Zeviani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antozzi, C.
Right arrow Articles by Zeviani, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1997, European Society of Cardiology

Cardiomyopathies in disorders of oxidative metabolism

Carlo Antozzia and Massimo Zevianib,c,*

aNeuromuscular Research Department, Istituto Nazionale Neurologico ‘Carlo Besta’, Milan, Italy
bDepartment of Biochemistry and Genetics, Istituto Nazionale Neurologico ‘Carlo Besta’, Milan, Italy
cDivision of Molecular Medicine, Children's Hospital Bambino Gesù, Rome, Italy

* Corresponding author. Istituto Nazionale Neurologico ‘Carlo Besta’, Via Celoria 11, 20133 Milan, Italy. Tel.: +39 (2) 2394257; fax: +39 (2) 2664236.

Primary cardiomyopathy is an important cause of mortality in children and adults. Apart from inherited disorders of myocardial contractile and structural proteins, several defects of energy metabolism may cause cardiomyopathy. Most of the energy required for myocardial contraction is derived from aerobic metabolism. Faulty aerobic metabolism involving the heart may be due to defects of mitochondrial oxidative phosphorylation or to defects of fatty acid oxidation. Considerable advances have been made in the last 10 years in understanding the biochemical and molecular characteristics of mitochondrial disorders. Several point mutations or large-scale re-arrangements of mitochondrial DNA have been identified in patients with cardiomyopathy, either as part of complex multisystem syndromes or as the main clinical feature. Inborn errors of fatty acid oxidation are reported with increasing frequency as a cause of metabolic dysfunction, myopathy, cardiomyopathy, and sudden death in childhood. Advances in biochemical and molecular genetic techniques have considerably improved our understanding of the metabolic disorders causing cardiomyopathy, providing new tools for classification and diagnosis of candidate patients. The present review focuses on defects of mitochondrial oxidative metabolism associated with cardiomyopathy.

KEYWORDS Cardiomyopathy; Mitochondrial DNA; Respiratory chain; β-Oxidation; Oxidative metabolism


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
HypertensionHome page
J. Scheuer
Fueling the Hypertrophied Heart
Hypertension, November 1, 2004; 44(5): 623 - 624.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. van Bilsen, P. J.H Smeets, A. J Gilde, and G. J van der Vusse
Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?
Cardiovasc Res, February 1, 2004; 61(2): 218 - 226.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
E. Fosslien
Mitochondrial Medicine - Cardiomyopathy Caused by Defective Oxidative Phosphorylation
Ann. Clin. Lab. Sci., October 1, 2003; 33(4): 371 - 395.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L Bindoff
Mitochondria and the heart
Eur. Heart J., February 1, 2003; 24(3): 221 - 224.
[Full Text] [PDF]


Home page
Eur Heart JHome page
D Holmgren, H Wahlander, B.O Eriksson, A Oldfors, E Holme, and M Tulinius
Cardiomyopathy in children with mitochondrial disease: Clinical course and cardiological findings
Eur. Heart J., February 1, 2003; 24(3): 280 - 288.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Lodi, B. Rajagopalan, A. M Blamire, J.M. Cooper, C. H Davies, J. L Bradley, P. Styles, and A. H.V Schapira
Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: An in vivo 31P magnetic resonance spectroscopy study
Cardiovasc Res, October 1, 2001; 52(1): 111 - 119.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
A. S. Clay, M. Behnia, and K. K. Brown
Mitochondrial Disease : A Pulmonary and Critical-Care Medicine Perspective
Chest, August 1, 2001; 120(2): 634 - 648.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. T. Coburn, F. F. Knapp Jr., M. Febbraio, A. L. Beets, R. L. Silverstein, and N. A. Abumrad
Defective Uptake and Utilization of Long Chain Fatty Acids in Muscle and Adipose Tissues of CD36 Knockout Mice
J. Biol. Chem., October 13, 2000; 275(42): 32523 - 32529.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T.-j. Liu, H.-c. Lai, W. Wu, S. Chinn, and P. H. Wang
Developing a Strategy to Define the Effects of Insulin-Like Growth Factor-1 on Gene Expression Profile in Cardiomyocytes
Circ. Res., June 22, 2001; 88(12): 1231 - 1238.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.